AstraZeneca PLC (LSE/STO/NYSE: AZN) announced on 16 November 2026 that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Baxfendy (baxdrostat) for adults with arterial hypertension insufficiently controlled by at least two antihypertensive medicines. If the European Commission grants formal approval, Baxfendy will become the first and only aldosterone synthase inhibitor (ASI) in the EU — a potential milestone for a condition affecting approximately 70 million uncontrolled hypertension patients across Europe. The recommendation is underpinned by statistically significant Phase III trial results published in the New England Journal of Medicine and The Lancet.

Key Points

  • AstraZeneca PLC (AZN) — global biopharmaceutical company headquartered in Cambridge, UK
  • CHMP has issued a positive opinion recommending EU approval of Baxfendy for uncontrolled and resistant hypertension in adults
  • Baxfendy 2mg reduced office systolic blood pressure by 15.7 mmHg in BaxHTN and 24-hour ambulatory systolic blood pressure by 16.6 mmHg in Bax24 from baseline
  • Investors should watch for the European Commission's formal approval decision and progress of regulatory filings in Japan and China

CHMP Positive Opinion Based on BaxHTN and Bax24 Phase III Trial Results

The CHMP's recommendation rests on two pivotal Phase III studies. In the BaxHTN trial, involving 796 randomised patients, Baxfendy 2mg produced an absolute reduction of 15.7 mmHg in mean seated systolic blood pressure from baseline at week 12, with a placebo-adjusted reduction of 9.8 mmHg (p<0.001). The Bax24 trial, enrolling 218 patients with resistant hypertension, showed an absolute 24-hour ambulatory systolic blood pressure reduction of 16.6 mmHg from baseline, with a placebo-adjusted reduction of 14.0 mmHg (p<0.0001). Both studies were published in peer-reviewed journals, lending additional scientific weight to the CHMP's positive opinion.

Baxfendy's First-in-Class Aldosterone Synthase Inhibitor Mechanism Targets a Key Hypertension Driver

Baxfendy is designed to selectively inhibit aldosterone synthase, the enzyme encoded by the CYP11B2 gene responsible for aldosterone production in the adrenal gland. Elevated aldosterone is a recognised driver of persistently uncontrolled hypertension, contributing to sodium and water retention and increased cardiovascular and renal risk. In clinical trials, Baxfendy significantly lowered aldosterone levels without affecting cortisol. AstraZeneca originally acquired baxdrostat through its purchase of CinCor Pharma, Inc. in February 2023, and the medicine is already approved in the United States and other countries as a first-in-class ASI.

Bax24 Target Attainment: 70.6% of Patients Achieved Ambulatory SBP Below 130 mmHg

A notable secondary finding from the Bax24 trial highlights the clinical magnitude of Baxfendy's effect. The announcement states that 70.6% of patients treated with Baxfendy achieved ambulatory 24-hour average systolic blood pressure below 130 mmHg, compared with 16.7% in the placebo group, representing an odds ratio of 15.2 (95% CI 6.6–35.2; p<0.0001). This threshold aligns with 2024 European Society of Hypertension guidelines. The number needed to treat was two, meaning for every two patients treated with Baxfendy instead of placebo, one additional patient achieved this blood pressure target at week 12.

AstraZeneca's Broader Baxfendy Pipeline Spans Kidney Disease, Heart Failure and Primary Aldosteronism

Beyond hypertension, AstraZeneca is investigating Baxfendy across several additional cardiorenal conditions. Active clinical programmes include trials of Baxfendy as monotherapy for primary aldosteronism, in combination with dapagliflozin for chronic kidney disease and hypertension, and for the prevention of heart failure in hypertensive patients. Regulatory filings are also currently under review in Japan and China. Investors may be watching whether the European Commission converts the CHMP's positive opinion into a formal marketing authorisation, and for further data readouts across the broader Baxfendy development programme, which forms part of AstraZeneca's stated ambition to bring 20 new medicines to patients by 2030.